NCT00244816 2025-10-23
Taxoprexin® Treatment for Advanced Eye Melanoma
American Regent, Inc.
Phase 2 Completed
Clinical Trials
10 trialsNCT00422877 2025-10-16
Taxoprexin® Treatment for Advanced Primary Cancers of the Liver, Gallbladder or Biliary Tract
American Regent, Inc.
Phase 2 Terminated
NCT00249262 2025-09-26
Taxoprexin Treatment for Advanced Skin Melanoma
American Regent, Inc.
Phase 2 Completed
NCT07136519 2025-08-22
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma
Affiliated Hospital of Guangdong Medical University
Phase 2 Not yet recruiting
NCT03831178 2025-06-26
DHA-WIN
AHS Cancer Control Alberta
Phase 2 Active not recruiting
NCT01849250 2021-12-28
Study of Docosahexaenoic Acid (DHA) in Triple Negative Breast Cancer Survivors
National Cancer Institute (NCI)
Phase 2 Completed
NCT03936621 2019-05-07
Omega
British Columbia Cancer Agency
Phase 2 Unknown
NCT01051154 2016-08-22
DHA-ALL
Coordinación de Investigación en Salud, Mexico
Phase 2 Completed
NCT01070355 2011-10-21
EMT
University of Leeds
Phase 2 Completed
NCT00455416 2008-05-21
KLYMF
Oslo University Hospital
Phase 2 Unknown